Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC. New research from the ...

Access to healthy food would address the rising rates of obesity, diabetes and heart disease and the psychological issues ...

Want to live longer? A new groundbreaking study reveals what to focus on for a healthy, long life and it is not weight loss.